Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Personal data of nearly half of the popular genetic testing company's customers -- 6.9 million people -- was exposed in the data breach.

These findings demonstrate disparities in precise genetic diagnosis are not due to diagnostic yields ... GeneDx is at the ...

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

Adjusted EPS was $0.31, significantly above the expected loss. The company is encouraged by preliminary results in testing ...

A growing demand for portable and point-of-care sequencers (NGS) is expected to drive the market for next-generation ...

Illumina Hong Kong LIMITED (Illumina), a global leader in DNA sequencing and array-based technologies, and PHASE Scientific ...

The DNA testing company is a holding of Cathie Wood's ARK Invest fund. Natera specializes in noninvasive genetic testing technology. Its main focuses are women's health, including preconception and ...

New Canadian university research is aiming to genetically reduce methane emissions from beef cattle, while making the ...

(“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are ... it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic ...